Receipt of previous approved or investigative immune modulatory agent within  days of receiving the first dose of treatment;
. Receipt of any investigational anti-cancer therapy within  weeks prior to first dose of TAB;
Receipt of any conventional or investigational anticancer therapy not otherwise specified within  days of the planned first dose.
Prior receipt of any investigational immunotherapy. Subjects may have received agents that have local health authority approval for the disease indication
Grade  or higher hypersensitivity reaction to prior receipt of any antibody therapy
Receipt of a therapeutic anticoagulant
Receipt of a stable ART regimen for at least  weeks prior to start of trial
Receipt of any type of anticancer antibody (including investigational antibody) within  weeks before planned first dose of study drug
Prior corticosteroids as anti-cancer therapy within a minimum of  days of first receipt of study drug
PART II: Greater than or equal to  week since receipt of standard or investigational HER-directed therapy for metastatic or recurrent disease
Receipt of tranexamic acid or other antifibrinolytics within  hrs prior to infusion
Patients receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy within  days of first receipt of study drug with the exception of: hydroxyurea (HU) in patients who need to continue this agent to maintain WBC count =< ,/mm^
Receipt of an investigational agent within  days (or  days for an antibody-based therapy) before the first planned dose of study drugs
Prior chemotherapy, radiation (other than short cycle of radiation to reduce bone pain), treatment with a VEGF inhibitor, PARP inhibitor or immunotherapy within  days of first receipt of study drug. Hormone therapy within  days of first receipt of study drug.
Receipt of Investigational agents within  days prior to first dose of protocol therapy.
Receipt of any anti-cancer therapy within  days of starting BP, with the exception of hydroxyurea or anagrelide, or TKI (within  days)
Less than  days between registration and the last receipt of chemotherapy, biotherapy, immunotherapy, radiotherapy (excluding palliative radiotherapy), or major surgery; prior receipt of immunomodulatory therapy (eg: nivolumab) is permitted, as long as there has been a  day washout period following the most recent treatment
Receipt of any investigational therapy is not permitted within  days prior to the first dose of nivolumab
Receipt of any conventional or investigational anticancer therapy not otherwise specified above within  days of  half-lives of the agent prior to the first dose of durvalumab and tremelimumab
Receipt of any anti-cancer therapy within  days prior to CD, with the exception of hydroxyurea or anagrelide (within  hours), TKI (within days), or a single dose of cytarabine (for proliferative disease)
Receipt of any investigational agent or study treatment within  days prior to CD
Receipt of therapies or procedures prior to first dose including:
Receipt of any other investigational agents within  days prior to study treatment
Receipt of an investigational agent within  days (or  days for an antibody-based therapy) before the first planned dose of study drugs
Receipt of sunitinib within  months of receiving tremelimumab
Subject who received any therapies intended to treat malignancy within  days of first receipt of DS-b
Participants receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy within  days from first receipt of study drug
Receipt of any type of small molecular kinase inhibitor (including investigational kinase inhibitors) within  weeks of enrollment or receipt of any anti-cancer therapy (including investigational therapy, monoclonal antibodies, cytokine therapy) within  weeks of enrollment
Prior receipt of an indoleamine ,-dioxygenase (IDO) inhibitor
Received any therapies intended to treat malignancy within  days of first receipt of DS-b (except for hydroxyurea, which must be discontinued at least  hours prior to study treatment).
Receipt of Gliadel therapy
Receipt of any systemic (oral, intravenous, or inhaled) antifungal therapy for this infection episode for  or more consecutive days (>=  hours) immediately before randomization.
Receipt of posaconazole or voriconazole as empirical treatment for this infection for  days ( hours) or more within the  days immediately before randomization.
Prior receipt of a PIM inhibitor
Receipt of all standard therapies for the tumor type:
Receipt of any systemic anticancer therapy within  days prior to the first dose of MEDI
Requirement of radiotherapy to treat brain metastases or receipt of any non-study systemic therapy for cancer or any other experimental/investigational treatment.
Receipt of any investigational medication within  weeks prior to randomization
Prior enrollment in NCI protocol -C- with receipt of at least  doses of TARP peptide vaccine (i.e. completion of primary vaccination series)
Prior receipt of cumulative RAI doses in excess of  mCi
Prior receipt of an IDO inhibitor.
Prior receipt of a BET inhibitor (Treatment Group B only).
Prior receipt of an LSD inhibitor including INCB (Treatment Group C only).
Receipt of any radiotherapy or hormonal therapy for cancer treatment within  days prior to first dose of study treatment
Receipt of any investigational medication within  weeks prior to enrollment
Receipt of anticancer therapy:
Receipt of any investigational medication within  weeks prior to enrollment
Receipt of an investigational agent within  days (or  days for an antibody-based therapy) before the first planned dose of study drugs
Receipt of any investigational medication within  weeks prior to enrollment
Receipt of any type of small molecular kinase inhibitor (including investigational kinase inhibitors) within  weeks or  half-lives (whichever is shorter) of enrollment or receipt of any anti-cancer therapy (including investigational therapy, monoclonal antibodies, cytokine therapy) within  weeks of enrollment
Receipt of anticancer therapy within  days prior to the first dose of Investigational Product
Patients who, in the opinion of the physician, would not be clinically appropriate for receipt of the therapy regimen associated with participation
Receipt of treatment with another investigational device or drug
Receipt of drug that will affect biologic response to radiation (radiosensitizer or radioprotector)
Receipt of any other investigational agents within  days prior to study enrollment
Receipt of an investigational agent within  days (or  days for an antibody-based therapy) before the first planned dose of study drugs
Receipt of an investigational agent within  days (or  days for an antibody-based therapy) before the first planned dose of study drugs; (immune checkpoint inhibitors that are antibody-based will only require  days before enrollment)
Receipt of any other investigational agent within the  days prior to Day .
Receipt of another investigational drug within  days of enrollment.
Gastrointestinal disease that interferes with receipt of oral drugs;
Receipt of investigational drugs within  days before D of alisertib
Receipt of treatment known to potentially affect the course of AA within last month
Receipt of any investigational agents within  days before the first dose of ibrutinib
Receipt of corticosteroids >  mg/day within  weeks prior tost dose
Receipt of any investigational agent within  weeks prior to st dose
Participation in a therapeutic research study or receipt of an investigational drug within  days of T-cell infusion
Receipt of any conventional or investigational anticancer therapy within  days prior to the first dose of MEDI.
Receipt of any investigational treatment within  weeks of scheduled dosing day .
Receipt of lapatinib within  days of scheduled dosing day .
At least two-weeks since receipt of prior standard or investigational therapy
Receipt of any conventional or investigational anticancer treatment within  days prior to the first dose of MEDI.
Receipt of investigational therapy in a clinical trial setting within  days of enrollment;
At least  days since receipt of chimeric antigen receptor therapy or other modified T cell therapy
Receipt of anticancer therapy:
Receipt of any BRAF inhibitor (in metastatic melanoma), or investigational anticancer therapy within  weeks prior to the first dose of MEDI (AMP-)
Receipt of an investigational drug within  days prior to initiation of study treatment
Participants receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy within  days of first receipt of study drug, with the exception of hydroxyurea as defined in protocol
Chemotherapy or any other investigational agents within  days of first receipt of study treatment, or major surgery within  days of first receipt of study treatment, or palliative radiation within  days of first receipt of study treatment
Receipt of an investigational drug within  days prior to study start
Receipt of other anticancer therapy within  -  weeks, depending on the treatment
Receipt of any investigational anticancer therapy within  days prior to the first dose of MEDI, or in the case of monoclonal antibodies (eg, bevacizumab),  days prior to the first dose of MEDI
Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitors) within  weeks of enrollment or receipt of any anti-cancer therapy (including investigational therapy, monoclonal antibodies, cytokine therapy) within  weeks of enrollment
Receipt of any conventional or investigational anticancer therapy within  weeks prior to the first dose of durvalumab and IPH
Prior participation, i.e., receipt of study medication, in this study;
Prior corticosteroids as anti-cancer therapy within a minimum of  days of first receipt of study drug
Receipt of intravenous immunoglobulin therapy (IVIG) <  days prior to calendar day of vaccination
FOR THE  SUBJECTS ENROLLED IN YEAR : Receipt of IVIG <  days prior to calendar day of vaccination
Receipt of intravenous immunoglobulin therapy (IVIG) <  days prior to vaccination
Receipt of ART for at least  days prior to randomization
Receipt of locoregional therapy (LRT) with verification of complete response at least  days following treatment
Receipt of any investigational agents within  days prior to commencing study treatment
Receipt of an investigational drug or device within  days of enrollment.
